BioSpace News Archive

Findings come from an NIH analysis of more than two decades of dietary data from 390,124 U.S. adults.

Mauna Kea Technologies, inventor of Cellvizio®, the multidisciplinary platform for probe-based and needle-based confocal laser endomicroscopy, unveils its new subsidiary CellTolerance, fully dedicated to its unique program for the detection and treatment of food intolerances associated with Irritable Bowel Syndrome.

Tevogen Bio Holdings Inc. filed a Registration Statement on Form S-1 on June 21, 2024, to register the issuance of previously disclosed shares of the Company’s common stock as well as the resale of shares of common stock and warrants by existing securityholders.

QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC) today announced that it will host a conference call on Thursday, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT to discuss topline data from the Company’s Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).

Aclarion, Inc. announced their initial payer coverage of Nociscan by AXA in London, UK in conjunction with The London Clinic, one of the UK’s largest and most renowned independent hospitals.

BioStem Technologies Inc. today announced that an article validating its proprietary processing method and its placental allograft products has been published in the international, peer-reviewed journal, Health Science Reports.

DiaCarta, Inc. (“DiaCarta”), a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic collaboration with Capstone Health Alliance, one of the largest regional group purchasing organizations (GPO) in the US healthcare sector.

Jaguar Health, Inc. today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC that Jaguar has regained compliance with Nasdaq’s minimum bid price requirement.

Korean scientists have investigated HVH-2930, an innovative HSP90 inhibitor in reshaping HER2-positive breast cancer treatment.